P53R172H and P53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Jul 12

PMID 38994678

Authors

Joy M McDaniel

Rhiannon L Morrissey

Denada Dibra

Lalit R Patel

Shunbin Xiong

Yun Zhang

Gilda P Chau

Xiaoping Su

Yuan Qi

Adel K El-Naggar

Guillermina Lozano

Affiliations

Soon will be listed here.

Abstract

Significance: Our findings implicate NR5A2 as a novel mediator of mutant p53 transcriptional activity in breast cancer. NR5A2 may be an important therapeutic target in hard-to-treat breast cancers such as endocrine-resistant tumors and metastatic triple-negative breast cancers harboring TP53 missense mutations.

References

Pang J, Molania R, Chand A, Knower K, Takano E, Byrne D . LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget. 2017; 8(48):83626-83636. PMC: 5663541. DOI: 10.18632/oncotarget.18886. View

Bae S, Nam S, Jung Y, Lee S, Park B, Lim W . Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. Breast Cancer Res Treat. 2018; 172(2):437-444. DOI: 10.1007/s10549-018-4928-2. View

Brosh R, Rotter V . When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009; 9(10):701-13. DOI: 10.1038/nrc2693. View

Michalek S, Brunner T . Nuclear-mitochondrial crosstalk: On the role of the nuclear receptor liver receptor homolog-1 (NR5A2) in the regulation of mitochondrial metabolism, cell survival, and cancer. IUBMB Life. 2020; 73(3):592-610. DOI: 10.1002/iub.2386. View

Kanayama T, Arito M, So K, Hachimura S, Inoue J, Sato R . Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities. J Biol Chem. 2007; 282(14):10290-8. DOI: 10.1074/jbc.M700270200. View

Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B . A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009; 137(1):87-98. DOI: 10.1016/j.cell.2009.01.039. View

Liu L, Li Y, Pan B, Zhang T, Wei D, Zhu Y . Nr5a2 promotes tumor growth and metastasis of gastric cancer AGS cells by Wnt/beta-catenin signaling. Onco Targets Ther. 2019; 12:2891-2902. PMC: 6489909. DOI: 10.2147/OTT.S201228. View

Makki J . Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol. 2016; 8:23-31. PMC: 4689326. DOI: 10.4137/CPath.S31563. View

Hoch R, Thompson D, Baker R, Weigel R . GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 1999; 84(2):122-8. DOI: 10.1002/(sici)1097-0215(19990420)84:2<122::aid-ijc5>3.0.co;2-s. View

10.

Grant C, Bailey T, Noble W . FIMO: scanning for occurrences of a given motif. Bioinformatics. 2011; 27(7):1017-8. PMC: 3065696. DOI: 10.1093/bioinformatics/btr064. View

11.

Joruiz S, Bourdon J . p53 Isoforms: Key Regulators of the Cell Fate Decision. Cold Spring Harb Perspect Med. 2016; 6(8). PMC: 4968168. DOI: 10.1101/cshperspect.a026039. View

12.

Freed-Pastor W, Mizuno H, Zhao X, Langerod A, Moon S, Rodriguez-Barrueco R . Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012; 148(1-2):244-58. PMC: 3511889. DOI: 10.1016/j.cell.2011.12.017. View

13.

Kim M, Lozano G . Mutant p53 partners in crime. Cell Death Differ. 2017; 25(1):161-168. PMC: 5729539. DOI: 10.1038/cdd.2017.185. View

14.

Heberle H, Meirelles G, da Silva F, Telles G, Minghim R . InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics. 2015; 16:169. PMC: 4455604. DOI: 10.1186/s12859-015-0611-3. View

15.

Rastelli F, Crispino S . Factors predictive of response to hormone therapy in breast cancer. Tumori. 2008; 94(3):370-83. DOI: 10.1177/030089160809400314. View

16.

Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L . Survival Outcomes by Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018. PMC: 6050977. DOI: 10.1200/PO.17.00245. View

17.

Li B, Murphy K, Laucirica R, Kittrell F, Medina D, Rosen J . A transgenic mouse model for mammary carcinogenesis. Oncogene. 1998; 16(8):997-1007. DOI: 10.1038/sj.onc.1201621. View

18.

Gu P, Goodwin B, Chung A, Xu X, Wheeler D, Price R . Orphan nuclear receptor LRH-1 is required to maintain Oct4 expression at the epiblast stage of embryonic development. Mol Cell Biol. 2005; 25(9):3492-505. PMC: 1084298. DOI: 10.1128/MCB.25.9.3492-3505.2005. View

19.

Yu X, Zhang Y, Xiong S, McDaniel J, Sun C, Chau G . Omics analyses of a somatic breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. Proc Natl Acad Sci U S A. 2022; 119(45):e2210618119. PMC: 9659373. DOI: 10.1073/pnas.2210618119. View

20.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View